Ceva to participate in the International Pig Veterinary Society Congress 2026

Ceva is proud to announce its participation in the 28th International Pig Veterinary Society Congress IPVS 2026, taking place from 16th to 19th June 2026 in Ho Chi Minh City, Vietnam, at Thiskyhall Sala Convention Center.

As a Diamond Sponsor of IPVS 2026, Ceva will join swine veterinarians, researchers, producers and industry experts from around the world to exchange scientific knowledge, share field experience and discuss the future of pig health and production.

Through a dedicated scientific programme, Ceva will highlight its commitment to advancing swine health by combining innovation, diagnostics, vaccination, field data and practical expertise.

Ceva to participate in IPVS 2026, the 28th International Pig Veterinary Society Congress

Ceva pre-symposium on 16th June 2026

Ahead of the main congress, Ceva will host an exclusive pre-symposium on 16th June 2026 at Nikko Hotel Saigon, Ho Chi Minh City, under the theme:

“Advancing Respiratory Health: Data, Diagnostics & Next-Generation Vaccination.”

The session will focus on key respiratory health challenges in pigs, with particular attention to PRRS, PCV2 and Mycoplasma hyopneumoniae. The programme will bring together international experts and Ceva specialists to discuss field challenges, disease evolution, economic impact, diagnostics and next-generation prevention strategies.

The pre-symposium agenda includes the following speakers, affiliations and session titles:

  • Cristian Gutiérrez-Jaramis (Ceva Animal Health). Advancing Swine Health: Ceva’s Commitment.
  • Professor Chanhee Chae (Seoul National University). PRRS Control in Practice: Field Challenges and Next-Generation Prevention.
  • Preben Mortensen (Ceva Animal Health). PRRS Control in Practice: Measuring Economic Benefits in the Field.
  • Professor Lars E. Larsen (University of Copenhagen). PCV2 Control in Practice: PCV2 divergence over four decades – tool for diagnostics and impact on disease severity and spread.
  • Professor Hans Nauwynck (Ghent University). PCV2 Control in Practice: Effect of PCV2 evolution on its behavior in host cells and vaccination efficacy.
  • Philippe Mazerolles (Ceva Animal Health). Advancing the PCV2 and M. hyo standard of care with CIRBLOC® M Hyo.
  • Guillermo Ramis (University of Murcia). PCV2 Subclinical Infections: What CIRBLOC® M Hyo shows us in Spain.

This dedicated session reflects Ceva’s focus on supporting veterinarians and producers with science-based solutions that help improve respiratory health outcomes on farms.

Two Ceva lunch symposiums during IPVS 2026

During the main congress, Ceva will host two lunch symposiums at Thiskyhall, 5th Floor, Sala Convention Center, Conference Hall 1, each dedicated to a key area of swine health.

The first lunch symposium, focused on Piglet Performance and Economics, will take place on 17th June 2026 from 12:00 to 13:00 under the title:

“Where Vets Meet Economists: The Economic Benefits of High-Quality Piglets.”

The session will feature Daniel Sperling, Assistant Professor at VETUNI Brno, and Robert Hoste, Senior Pig Production Economist at Wageningen University & Research.

Ceva symposiums during IPVS 2026 Daniel Sperling and Robert Hoste

The second lunch symposium, focused on the Sow Health, will be held on 18th June 2026 from 12:00 to 13:00 under the title:

“Don’t underestimate Flu and PRRS impact on your farm.”

The session will feature Julia Stadler, Senior Academic Assistant at Ludwig-Maximilians Universität, and Preben Mortensen, Corporate Swine Technical Services Manager at Ceva Animal Health.

This symposium will focus on the field impact of swine influenza and PRRS, two diseases that continue to play an important role in respiratory health, farm performance and disease control strategies.

Ceva symposiums during IPVS 2026 Julia Stadler and Preben Mortensen

Ceva abstracts at IPVS 2026

In addition to its symposium programme, Ceva will contribute to IPVS 2026 through a broad selection of abstracts covering some of the most relevant topics in swine health, including respiratory disease, PCV2, M. hyo, PRRS, lung lesions, piglet quality, enteric health, sow vaccination, oedema disease, coccidiosis, anaemia and field monitoring tools.

All scientific contributions listed below are included as abstracts, in line with the information available for the event.

Abstracts by main responsible author 

Abstract focused on Prevalence of Actinobacillus pleuropneumoniae serotypes in clinical pigs from Southeastern Vietnam, contributing local epidemiological insights into respiratory disease monitoring.

Abstract focused on Mycoplasma hyopneumoniae, PCV2, combined vaccination protocols, performance outcomes, economic impact and lung lesion monitoring. Topics include:

  • Mycoplasma hyopneumoniae quantification depending on the vaccination status of pigs.
  • Comparison of three combined vaccines against PCV2 + M. hyopneumoniae on performance parameters in pigs under field conditions.
  • Comparison of two commercial porcine circovirus type 2 and Mycoplasma hyopneumoniae combined vaccines on performance parameters and economic impact.
  • Field evaluation and economic impact of a new ready-to-use vaccine containing Mycoplasma hyopneumoniae and PCV2d in a fattening farm with severe respiratory disease.
  • Updated regional assessment in four European countries of PRDC pathogens using lung lesion scoring and screening PCR.
  • A pan-European assessment of slaughterhouse lung lesions in pigs: 2025 survey findings.
  • Comparison of two PCV2/Mhyo RTU vaccine protocols on performance effects and economic benefits.

Abstract focused on PCV2 epidemiology, specifically the prevalence of porcine circovirus type 2 genotypes in Russia.

Abstracts focused on PCV2 and M. hyopneumoniae combined vaccination, piglet quality and PRRS vaccine return on investment. Topics include:

  • Comparison of two commercial porcine circovirus type 2 and Mycoplasma hyopneumoniae combined vaccines on antibody response and mortality in nursery pigs under field conditions.
  • Effects of injectable combined gleptoferron and toltrazuril on enhancing the quality of weaned piglets.
  • Parallel, randomised field efficacy and return-on-investment study of a next-generation PRRSV2-MLV vaccine compared to a conventional PRRSV1-MLV vaccine in a PRRSV1+2 endemic herd.

Abstracts covering lung lesion scoring, PCV2 vaccination, sow and piglet infection status, oedema disease, toltrazuril and comparative vaccine field data in China. Topics include:

  • Seasonal comparison and analysis of lung lesion scoring in slaughtered pigs from a Chinese company.
  • Etiological investigation of Melanosis Coli in slaughter pigs.
  • Infection status of sows and piglets from different farms of a Chinese group company following routine PCV2 vaccination.
  • A comparative study on the influence of long-term vaccination of a breeding herd against PCV2 in a subclinically infected farm.
  • Field efficacy of vaccination against oedema disease on a Chinese swine farm.
  • Study on the effects of toltrazuril on production performance in suckling and nursery piglets.
  • A comparative study on the effects of Porcine Circovirus 2 sow vaccination in a PCV2 subclinically infected farm.
  • Comparative analysis of slaughter lung scores and field data of two commercial Mycoplasma hyopneumoniae & PCV2 vaccines in a Chinese company.

Abstracts focused on PRRS vaccination, field efficacy and return on investment, particularly in farms with PRRSV2 or concurrent PRRSV1 and PRRSV2 circulation. Topics include:

  • Parallel, randomised field efficacy and return-on-investment study of a next-generation PRRSV2-MLV vaccine compared to a conventional lineage 7 based PRRSV2 MLV vaccine.
  • Parallel, randomised field efficacy and return-on-investment study of a next-generation PRRSV2-MLV vaccine compared to a conventional lineage 1 based PRRSV2-MLV vaccine in a type 1+2 endemic swine herd.
  • Comparative field evaluation of a next-generation CPD MLV PRRS vaccine versus a traditional MLV in a farm with concurrent PRRSV1 and PRRSV2 circulation.

Abstract focused on the economic impact of respiratory disease, estimating the economic loss due to Mycoplasma-like lung lesions in Denmark.

Abstract based on a longitudinal slaughterhouse survey exploring the seasonality of Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae lung lesions in Taiwanese swine farms from 2021 to 2024.

Abstracts focused on pneumonia, pleurisy, slaughterhouse lung scoring and economic impact. Topics include:

  • Economic impact of pneumonia and pleurisy on lung disposal costs and meat yield in two German slaughterhouses.
  • Comparison of two different lung scoring methods for detecting pneumonia and pleurisy in slaughterhouses.

Abstracts focused on lung lesion trends in Spain and Actinobacillus pleuropneumoniae antibody dynamics in sows and piglets. Topics include:

  • Evolution of the prevalence and severity of lung lesions assessed in slaughterhouses in Spain from 2016 to 2025.
  • Seasonality and incidence of slaughterhouse-assessed lung lesions in Spain.
  • Half-life of maternally derived antibodies against Actinobacillus pleuropneumoniae Apx-toxins and OmpA protein in a commercial farm.
  • Relationship between antibodies against Actinobacillus pleuropneumoniae toxins in sows and their piglets at 24 hours of life.
  • Detection of ApxII-toxin antibodies in a farm negative to Actinobacillus pleuropneumoniae.

Abstracts focused on enteric health, piglet quality, Cystoisospora suis, toltrazuril, gleptoferron, iron supplementation and oedema disease. Topics include:

  • Effect of the vaccination against Shiga toxin 2e in a piglet producing farm with subclinical Oedema Disease in Japan.
  • Cystoisospora suis in Japan: a pilot study on farm positivity, management and risk factors.
  • Efficacy of injectable toltrazuril against experimentally induced cystoisosporosis in piglets: effects on performance, intestinal integrity and immune stimulation.
  • Effect of parenteral iron in different doses on the course of Cystoisospora suis infection in piglets.
  • Comparison of injectable toltrazuril-gleptoferron and oral toltrazuril + iron dextran for the prevention of anaemia and coccidiosis under field conditions on a large-scale farm in Vietnam.
  • Together, these accepted abstracts reflect Ceva’s commitment to generating scientific evidence and real-world data that can support veterinarians and producers in making informed decisions for swine health management.

Supporting a healthier and more sustainable swine industry

Ceva’s participation in IPVS 2026 underlines its commitment to advancing swine health through science, innovation and collaboration.

By combining an exclusive respiratory pre-symposium, two lunch symposiums focused on the Enteric and Sow ranges, and a strong portfolio of accepted abstracts, Ceva will use IPVS 2026 as an opportunity to share knowledge, exchange field experience and support veterinarians and producers in addressing today’s most important swine health challenges.

Join Ceva at IPVS 2026 in Ho Chi Minh City, Vietnam, from 16th to 19th June 2026.